Inhalation formulation technologies
Skyepharma has a range of proprietary inhalation formulation technologies to enhance performance or overcome challenges in the development of Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) products. These technologies can also be applied to nasal and nebuliser formulations.
Our technologies are available for licensing by our partners for incorporation into in-house developments. Alternatively we can apply these technologies on your behalf in our own GMP laboratories to solve complex formulation challenges in the development of a wide range of inhalation products.
Technology Application Benefit
SkyeProtect™
Addition of magnesium stearate to DPI formulations
Improved dose uniformity and stability, especially with respect to moisture
SkyeDry™
Addition of sodium cromoglycate to MDI formulations
Improved stability especially with moisture sensitive compounds
SkyeStabe™
Addition of magnesium stearate to MDI formulations
Improved physical stability, dose uniformity and extension of storage shelf-life
SkyeFine™
Addition of CO2 or N2O to MDI formulations
Finer MDI aerosols, enabling a significant increase in respirable dose
IDD®-P
Production of sub-micron particles stabilised in HFA propellant for pMDI delivery
Targeted delivery of drug to the small airways (e.g. for systemic delivery) or enhanced efficacy